SCHEDULING STATUS: S4

PROPRIETARY NAME (AND DOSAGE FORM):
ULTRAMOX 500 (capsules)

COMPOSITION:
Amoxycillin trihydrate BP available as:
Gelatin capsules containing the equivalent of 500 mg amoxycillin.

PHARMACOLOGICAL CLASSIFICATION:
A 20.1.2 Penicillins.

PHARMACOLOGICAL ACTION:
(a) Bacteriology
(i) Spectrum
Amoxycillin is a penicillinase-susceptible penicillin and is, therefore, contra-indicated in infections caused by penicillinase-producing organisms. ULTRAMOX exhibits in vitro, and in experimental animals in vivo, bactericidal activity against a wide range of Gram-negative and Gram-positive organisms including:

Gram-positive bacteria:	Gram-negative bacteria:
Staphylococcus aureus (penicillin-sensitive)	Neisseria gonorrhoeae
Streptococcus pyogenes	Neisseria meningitidis
Streptococcus viridans	Haemophilus influenzae
Streptococcus faecalis	Bordetella pertussis
Diplococcus pneumoniae	Escherichia coli
Corynebacterium species	Salmonella typhi
Clostridium species	Salmonella species
Bacillus anthracis	Shigella species
	Brucella species
	Proteus mirabilis

(ii) Bactericidal Action
In Vitro: ULTRAMOX exerts a more rapid bactericidal action than other beta-lactam antibiotics against susceptible Escherichia coli. At similar inhibitory concentrations, ULTRAMOX results in a greater degree of bacterial cell lysis than other beta-lactam antibiotics against susceptible E. coli.
In Vivo: ULTRAMOX has been shown to exert greater therapeutic activity than ampicillin at similar blood levels in certain experimental infections.

(b) Absorption
ULTRAMOX is extremely well absorbed orally. After oral administration, there is no significant difference between the peak serum levels in fasting and non-fasting subjects. The presence of food does not interfere with the absorption of ULTRAMOX. ULTRAMOX may, therefore, be taken with meals. There is a linear/dose response in peak serum levels after oral administration.

(c) Distribution
i) Sputum: The concentration of amoxycillin in sputum does not decrease as occurs with ampicillin as purulence subsides.
ii) Bile: ULTRAMOX is present in bile obtained from a common bile duct drain of a healthy gall-bladder, however biliary levels are lower when the gall-bladder is diseased and absent in the presence of biliary tract obstruction.
iii) Urine: The average concentration of ULTRAMOX in urine collected during the first six hours after a 250 mg oral dose, is 580 µg/ml.
iv) CSF: There is insufficient evidence at present to show that ULTRAMOX penetrates into the cerebra-spinal fluid in therapeutic quantities and it should, therefore, not be used in the treatment of cerebra-spinal infections.

(d) Excretion
i) Renal: Approximately 60 % of an oral dose of ULTRAMOX is excreted unchanged in the active form into the urine within six hours.
ii) Biliary: A variable percentage of ULTRAMOX is excreted into the bile.

(e) Probenecid
Even higher ULTRAMOX serum levels may be achieved after oral administration to patients with normal renal function, by the simultaneous administration of a renal blocking agent such as probenecid. Probenecid should not be given in the presence of abnormal renal function.

INDICATIONS:
Infections caused by susceptible, non-penicillinase-producing organisms including:

Upper respiratory tract infections	Skin & soft tissue infections
Lower respiratory tract infections	Gonorrhoea
Otitis media	Non-specific urethritis
Upper urinary tract infections	Typhoid Fever
Lower urinary tract infections	Gastro-intestinal tract infections

CONTRAINDICATIONS:
Allergy to penicillins is an absolute contra-indication to the use of ULTRAMOX.

WARNINGS AND SPECIAL PRECAUTIONS
The use of this antibiotic may lead to the appearance of resistant strains of organisms and sensitivity testing should, therefore, be carried out wherever possible, to ensure the appropriateness of the therapy.

DOSAGE AND DIRECTIONS FOR USE:
The average adult dose for ULTRAMOX is 750 mg - 1,5 g per day, but in serious infections up to 6 g daily has been administered without harmful effects.

(a) General dosages:
Adults: 250 mg (1 x 250 mg capsule) three times a day.
In severe infections these dosages may safely be increased.

(b) Specific Dosages:

Indications	Daily Dosages Adults	Children	Duration
Gastro intestinal tract infections	1 - 2 g	-	4 -5 days
Acute typhoid Fever	4 g -	- 100 mg/kg	14 days 21 days
Gonorrhoea	2 - 3 g	-	Stat

**Gonorrhoea: Some venereologists have found that greater clinical success has been achieved by using probenecid in conjunction with ULTRAMOX therapy.

SIDE-EFFECTS:
As with other penicillins side-effects are rare and usually of a mild and transitory nature. Allergic reactions may occur, and these are normally mild in nature, presenting as a pruritic skin rash, an erythematous skin reaction or urticaria. In this event withdrawal of ULTRAMOX and administration of an antihistamine will suffice in most cases.
Should a serious anaphylactic reaction occur, ULTRAMOX should be discontinued and the patient treated with the usual agents: Adrenalin, corticosteroids and antihistamines.
Treatment with ULTRAMOX may give rise to a maculopapular rash during therapy or within a few days after completion there of. The incidence of maculopapular rash is especially high in patients suffering from infectious mononucleosis.
Caution must be exercised in treating patients with dehydration or oliguria because of the possibility of crystalluria.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
No known symptoms of overdosage.
As with all penicillins, oral administration can cause gastro-intestinal symptoms such as transient diarrhoea, nausea and colic which are dose-related and a result of local irritation not toxicity.

IDENTIFICATION:
Flesh/maroon coloured capsules overprinted "ULTRAMOX 500".

PRESENTATION:
Blisters and Patient Ready packs of 15's and 100's and canisters containing 15 or 100 or 500 capsules.

STORAGE INSTRUCTIONS:
Store at or below 25˚C in a dry place.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:
Y/20.1.2/101

NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION:
Oethmaan Biosims (PTY) Ltd.
207A Sherwood House
Greenacres Office Park
c/o Victory and Rustenburg Roads
Victory Park
Johannesburg
2195

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
10 May 1991

IP172002

180 mm

280 mm

SKEDULERINGSTATUS: S4

EIENDOMSNAAM (EN DOSEERVORM):
ULTRAMOX 500 (Kapsules)

SAMESTELLING:
Amoksisilliëntri hidraat BP beskikbaar as:
Gelatien kapsules wat die ekwivalent van 500 mg amoksisillien bevat.

FARMAKOLOGIESE KLASSIFIKASIE:
A20.1.2 Penisilliene.

FARMAKOLOGIESE WERKING:
(a) Bakteriologie
(i) Spektrum
Amoksisillien is 'n penisillien vatbaar vir penisillinase en is daarom nie aangedui by infeksies veroorsaak deur 'n kiemdodende werking in vitro, en in eksperimentele diere in vivo, teen 'n wye reeks Gram-negatiewe en Gram-positiewe organismes, insluitende:

Gram-positiewe bakterieë:	Gram-negatiewe bakterieë:
Staphylococcus aureus (penisilliensensitief)	Neisseria gonorrhoeae
Streptococcus pyogenes	Neisseria meningitidis
Streptococcus viridans	Haemophilus influenzae
Streptococcus faecalis	Bordetella pertussis
Diplococcus pneumoniae	Escherichia coli*
Corynebacterium spesies	Salmonella typhi
Clostridium spesies	Salmonella spesies
Bacillus anthracis	Shigella spesies
	Brucella spesies
	Proteus mirabilis

(ii) Kiemdodende werking
In-vitro: ULTRAMOX oefen 'n vinniger kiemdodende werking uit een gevoelige Escherichia coli as ander beta-laktam antibiotika. Teen soortgelyke inhiberende konsentrasies veroorsaak ULTRAMOX 'n groter mate van bakteriele sel-lise as ander beta-laktam antibiotika teen gevoelige Escherichia coli.
In vivo: Dit is gewys dat ULTRAMOX 'n groter terapeutiese werking, as ampisillien met soortgelyke bloedvlakke, by sekere eksperimentele infeksies, uitoefen.

(b) Absorpsie
ULTRAMOX word besonder goed na mondelikse toediening geabsorbeer. Na mondelikse toediening was daar geen noemenswaardige verskil tussen die spitsserumpeile van vastende en nie-vastende persone nie. Die absorpsie van ULTRAMOX word nie deur die teenwoordigheid van voedsel belemmer nie. ULTRAMOX kan dus saam met voedsel geneem word.
Daar is 'n lineere/dosis reaksie in spitsserumpeilie na beide mondelikse en parenterale toediening.

(c) Verspreiding
(i) Sputum: Die konsentrasie van amoksisillien in sputum verminder nie soos met ampisillien die geval is, wanneer purulensie afneem nie.
(ii) Gal: ULTRAMOX is teenwoordig in gal wat van 'n gemeenskaplike galbuis-dreineerbui s van 'n gesonde galblaas verkry is, maar galpeile is laer in 'n gemfekteerde galblaas en afwesig met galbuisverstopping.
(iii) Urien: Die gemiddelde konsentrasie ULTRAMOX wat in urien, binne ses uur na 'n 250 mg dosis, gevind is, is 580 µg/ml.
(iv) S.S.V.: Daar is tot datum nie genoegsame bewyse dat ULTRAMOX die serebrospinale vog in terapeutiese hoeveelhede binnedring nie en dit meet dus nie in serebrospinale infeksies gebruik word nie.

(d) Uitskeiding:
(i) Nieruitskeiding: Ongeveel 60% van 'n mondelikse dosis ULTRAMOX word onveranderd in die aktiewe vorm binne ses uur in die urien uitgeskei.
(ii) Galuitskeiding: Wisselende persentasies ULTRAMOX word in die gal uitgeskei.

(e) Probenesied
Na mondelikse toediening van ULTRAMOX aan pasiente met 'n normale nierwerking kan selfs hoer ULTRAMOX serumpeile, met die gelyktydige toediening van 'n nierversperder soos probenesied, bereik word. In die teenwoordigheid *van* abnormale nierwerking behoort probenesied nie toegedien word nie.

INDIKASIES:
Infeksies veroorsaak deur vatbare organismes wat nie penisillinase produseer nie, insluitende:

Boonste lugweginfeksies	Vel en sagteweefsel infeksies
Onderste lugweginfeksies	Gonorree
Otitis media	Nie-spesifieke uretritis
Boonste urienweginfeksies	Ingewandskoors
Onderste urienweginfeksies	Dermkanaal infeksies

KONTRA-INDIKASIES:
Allergie vir penisilliene is 'n totale kontra-indikasie vir die gebruik *van* ULTRAMOX.

WAARSKUWINGS EN VOORSORGMAATREËLS
Die gebruik van hierdie antibiotikum kan tot die verskyning van weerstandige stamme van organismes aanleiding gee.
Sensitiwiteitstoetse behoort daarom, waar moontlike, uitgevoer te word, om die paslikheid van terapie te verseker.

DOSIS EN GEBRUIKSAANWYSINGS:
Die gemiddelde dosis ULTRAMOX vir volwassenes is 750 mg - 1,5 g daagliks, maar by ernstige infeksies is tot 6 g daagliks, sonder nadelige gevolge, toegedien.

(a) Algemene doserings:
Volwassenes: 250 mg (1 x 250 mg capsule) drie maal per dag.
By ernstige infeksies kan die dosisse met veiligheid vermeerder word.

(b) Spesifieke Doserings:

Aanwysings	Daaglikse Doserings Volwassenes		Duur
Dermkanaalinfeksies	1 - 2 g	–	4 - 5 dae
Ingewandskoors –	4 g –	– 100 mg/kg	14 dae 21 dae
Gonorree	2 - 3 g	–	Stat

**Gonorree: Sommige venereoloe het gevind dat met die gebruik van probenesied saam met ULTRAMOX terapie, groter kliniese sukses behaal word.

NEWE-EFFEKTE:
Soos met ander penisilliene, is die newe-effekte seldsaam, lig en van verbygaande aard.
Allergiese reaksies kan voorkom en dit is normaalweg lig van aard en verskyn as 'n pruritiese huiduitslag, 'n eriteemagtige huidreaksie of galbuite. In die geval sal die onttrekking van ULTRAMOX en die toediening van 'n antihistamien, in meeste gevalle voldoende wees.
Indien 'n ernstige anafilaktiese reaksie plaasvind, moet ULTRAMOX onttrek en die pasient met die gewone middels (adrenalien, kortikosteroïede en antihistamiene) behandel word.
Behandeling met ULTRAMOX kan aanleiding gee tot 'n makulopapulere uitslag, of gedurende, of 'n paar dae na die terapie voltooi is. Die voorkoms van makulopapulere uitslag is veral hoog by pasiente wat aan infektiewe mononukleose ly.
Versigtigheid moet beoefen word met die behandeling van pasiente met ontwatering of oligurie weens die moontlikheid van kristallurie.

BEKENDE SIMPTOME VAN OORDOSERING EN BESONDERHEDE VAN DIE BEHANDELING DAARVAN:
Geen simptome van oordosering bekend nie.
Soos met alle penisilliene, kan mondelikse toediening dermkanaal simptome soos verbygaande diaree, naarheid en koliek veroorsaak, wat van die dosis afhang en deur lokale irritasie en nie toksisiteit veroorsaak word nie.

IDENTIFIKASIE:
Vlees/maroen gekleurde kapsules met "ULTRAMOX 500" daarop gedruk

AANBIEDING:
Pasiëntregpakke en stulpstroke van 15's en 100's en houers wat 15 of 100 of 500 kapsules bevat.

BERGINGSAANWYSINGS:
Berg teen of benede 25 °C op 'n droë plek.
HOU BUITE BEREIK VAN KINDERS

REGISTRASIENOMMER:
Y/20.1.2/101

NAAM EN BESIGHEIDSADRES VAN DIE HOUER VAN DIE REGISTRASIESERTIFIKAAT:
Oethmaan Biosims (EDMS) Bpk.
207A Sherwood House
Greenacres Besigheidspark
h/v Victoryweg en Rustenburgweg
Victory Park
Johannesburg
2195

DATUM VAN PUBLIKASIE VAN HIERDIE VOUBILJET:
10 Mei 1991

IP172002

180 mm

280 mm